Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 3
- Basım Tarihi: 2013
- Doi Numarası: 10.1097/coc.0b013e318243913f
- Dergi Adı: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.215-223
- Anahtar Kelimeler: breast cancer, mRNA, response to neoadjuvant chemotherapy, survivin, GSTP1, topoisomerase 2A, GLUTATHIONE-S-TRANSFERASE, SURGICAL ADJUVANT BREAST, ANTHRACYCLINE-BASED CHEMOTHERAPY, PROJECT PROTOCOL B-27, II-ALPHA, PREOPERATIVE CHEMOTHERAPY, ESOPHAGEAL CANCER, SYSTEMIC THERAPY, TAXOL RESISTANCE, DRUG-RESISTANCE
- İstanbul Üniversitesi Adresli: Evet
Özet
Introduction: The primary aim of this study is to investigate the effect of change in the expression levels of survivin, glutathione-S-transferase P1 (GSTP1), and topoisomerase 2 alpha (TOP2A) on the response to antracyclin-based and taxane-based neoadjuvant chemotherapy.